Abstract:Abstract Lung cancer remains one of the most common and deadly diseases worldwide, with a 5-year survival rate of 16%. It is still the leading cause of cancer-associated mortality among both men and women, despite a decreasing incidence rate over the past decade. MicroRNAs (miRNAs), a class of small non-coding RNAs, may regulate the expression of one third of all human genes and are related to carcinogenesis through their function as oncogenes or tumor suppressors. Circulating serum miRNAs that are differentially expressed between early stage lung cancer patients and controls could serve as non-invasive biomarkers for the early detection of lung cancer. In this study, we assessed a total of 89 candidate miRNAs using a quantitative Real-Time PCR method in 200 Caucasian, early stage lung cancer patients (stage I or II disease) and 200 Caucasian healthy controls. We used the rank sum test to assess differential serum miRNA expression levels between cases and controls. Odds ratios [OR] and 95% confidence intervals [CI] were calculated using multivariate logistic regression while adjusting for age, gender and smoking status. Of the 89 candidate miRNAs, 56 miRNAs were expressed in the serum of study subjects and 4 miRNAs (mir409_3p, mir223star, mir152, mir378) exhibited significant differential expression between cases and controls. The most significant association was observed for mir409_3p with a rank-sum test p-value at 0.008. In the stratified analysis, significant association was observed for mir409_3p in younger individuals less than or equal to 65 years of age, mir223star, mir152, and mir378 in older individuals greater than 65 years of age, mir409_3p and mir223star in males, mir152 in females, and mir378 in ever smokers. After dichotomizing serum miRNAs using the 1st quartile cut-off in the controls and comparing to the lowest quartile, we also observed significant associations for mir409_3p, mir223star, mir152, and mir378 with ORs (95% CI) of 0.47 (0.27-0.83), 2.00(1.03-3.88), 0.43(0.25-0.74), and 2.58(1.37-4.86), respectively. Risk score analysis using these 4 miRNAs showed significant increased risk of lung cancer with an increasing risk score (P = 1.64 X 10-6). Under Receiver Operating Characteristic curve analysis, the area under the curve (AUC) for age, gender, and smoking status is 0.76 while AUC increased to 0.81 with the addition of the serum miRNA data. We further downloaded the miRNA expression data from TCGA and found that mir378 and mir152 were available. These two miRNAs exhibited consistent associations (up-regulated for mi378 or down-regulated for mir152) while comparing tumor and normal tissues in lung patients with pathological stage I and II disease and comparing serum in lung cancer cases and controls. In conclusion, serum miRNAs exhibited differential expression between early stage lung cancer cases and controls and could be used for the early detection of lung cancer. Citation Format: Yuanqing Ye, Yan Wang, Jack Roth, Xifeng Wu. Serum MicroRNAs as biomarkers in early stage non-small cell lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 298. doi:10.1158/1538-7445.AM2014-298

Nine miRNAs expression differences and its significance in serum and peripheral blood mononuclear cell of lung cancer

Expression and Clinical Significance of Serum MicroRNA -21 in Different Stage Lung Carcinoma and in Pulmonary Bulla Patients

Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer

Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients

Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.

Expression Level of Serum Mirna-22 and Its Clinical Significance in Patients with Lung Cancer

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer

Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.

miR-22 and miR-126 expression in serum of patients with non-small cell lung cancer and its clinical significance

Altered Mir-143 and Mir-150 Expressions in Peripheral Blood Mononuclear Cells for Diagnosis of Non-Small Cell Lung Cancer.

Expression of microRNA-150 in Peripheral Blood and Its Clinical Significance in Patients with Non-Small Cell Lung Cancer

Deregulated Expression of Mir-21, Mir-143 and Mir-181A in Non Small Cell Lung Cancer is Related to Clinicopathologic Characteristics or Patient Prognosis

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers.

Differential Expression Profiles of Micrornas As Potential Biomarkers for the Early Diagnosis of Lung Cancer.

Abstract 298: Serum MicroRNAs As Biomarkers in Early Stage Non-Small Cell Lung Cancer

Prognostic Value of Microrna-10B Overexpression in Peripheral Blood Mononuclear Cells of Nonsmall-Cell Lung Cancer Patients

Diagnostic value of the detection of MicroRNAs in sputum of patients with non-small cell lung cancer

Expression of miR-219-5p, miR-19b-1 and miR-25 in the Serum of Osteosarcoma Patients and Their Correlations with Lung Metastasis

Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer

Expression of miRNA-29s in non-small cell lung cancer and its clinical significance

A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma